All In Biotech

NDA 022271 · Takeda Pharms USA

Nesina

Alogliptin Benzoate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jan 25, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

6

1 Phase 3, 0 recruiting

FAERS reports

3,416

2,992 serious, 356 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 11, 2025.

Alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin tablet is not recommended for use in patients with type 1 diabetes mellitus.

Mechanism: Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes mellitus, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NESINA · ALOGLIPTIN BENZOATE EQ 12.5MG BASE · TABLET, ORAL · Prescription
  • NESINA · ALOGLIPTIN BENZOATE EQ 25MG BASE · TABLET, ORAL · Prescription
  • NESINA · ALOGLIPTIN BENZOATE EQ 6.25MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alogliptin Benzoate" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea133
  • nausea123
  • vomiting110
  • pemphigoid102
  • acute kidney injury101
  • rash97
  • malaise93
  • dyspnoea86
  • blood glucose increased84
  • pneumonia84
  • decreased appetite80
  • pruritus78

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201112
201275
2013202
2014272
2015286
2016272
2017275
2018339
2019343
2020287
2021259
2022186
2023214
2024238
2025129
202627

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nesina (Alogliptin Benzoate)

2024 spending

$103K

Beneficiaries

152

278 claims

Per beneficiary

$675

$11.68 per unit

View as table
YearSpending
2020$618,459
2021$359,585
2022$372,583
2023$399,672
2024$102,672

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.